A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 1randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects